Creyon
3 known investors
Find your way into Creyon
187 people in our graph share verified history with the Creyon team — schools, employers, funds. One of them is your warm intro.
Viswa Sankaranarayananunlockedknows Matthew Levy · together at The University of Texas at Austin (overlapped)
×6knows the team · via The University of Texas at Austin
×2knows the team · via UC San Diego
×3knows the team · via Albert Einstein College of Medicine
Creyon develops aptamer-delivered oligonucleotide therapeutics for targeted cell-specific delivery, including small interfering RNA and antisense oligonucleotides. The company's platform addresses limitations in tissue penetration and immunogenicity for central nervous system and other tissue-targeted applications.
Founders & leadership
ML
Matthew LevyinCo-founderMatthew Levy is a nucleic acid and biochemist with over 20 years of experience in oligonucleotide therapeutics. He was an Associate Professor of Biochemistry at Albert Einstein College of Medicine, where he led a research laboratory focused on aptamer development and protein engineering, and subsequently served as VP of Discovery at Vitrisa Therapeutics before co-founding Creyon.
Investors · 3
In the news
Frequently asked questions
- What does Creyon do?
- Creyon develops aptamer-delivered oligonucleotide therapeutics for targeted cell-specific delivery, including small interfering RNA and antisense oligonucleotides. The company's platform addresses limitations in tissue penetration and immunogenicity for central nervous system and other tissue-targeted applications.
- Who founded Creyon?
- Creyon was founded by Matthew Levy.
- Who are Creyon's investors?
- Creyon's investors include Lux Capital, Tenmile, DCVC Bio.